Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Appointed director
Statera Biopharma, Inc. (CBLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/01/2023 8-K Quarterly results
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
11/15/2022 8-K Quarterly results
11/04/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: " ",
" "
10/27/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/17/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: " "
09/27/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/03/2022 8-K Changes in Registrant's Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: " "
06/22/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
04/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod FORT COLLINS, CO., April 13, 2022 /Globe Newswire/ — Statera Biopharma , a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company has agreed to enter into a strategic agreement with Coeptis Therapeutics, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, to sell Statera’s rights to Entolimod and other related toll-like receptor 5 agonists. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Coeptis financing. “Coeptis’ commitment to cancer the..."
04/15/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
03/31/2022 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "Resignation Letter of Randy Saluck"
03/25/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/22/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: " "
02/25/2022 8-K Quarterly results
02/22/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: " "
02/07/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: " ",
" ",
" ",
" ",
" "
01/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of McGuireWoods LLP"
12/20/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID"
12/14/2021 8-K Quarterly results
12/01/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
11/10/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/29/2021 8-K Quarterly results
09/28/2021 8-K Quarterly results
09/01/2021 8-K Quarterly results
08/17/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
08/09/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn’s Disease, Hematology, Pancreatic Cancer and COVID-19"
08/02/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, by and among Cytocom, Inc. and Avenue Venture Opportunities Fund, L.P",
"Supplement to the Loan and Security Agreement between Cytocom, Inc. and Avenue Venture Opportunities Fund, L.P",
"Warrant to Purchase Shares of Common Stock of Cytocom Inc., issued to Avenue Venture Opportunities Fund, L.P",
"Amended and Restated Share Purchase Agreement, by and among GEM Global Yield LLC SCS, GEM Yield Bahamas Limited and Cytocom Inc",
"Warrant to Purchase Shares of Cytocom Inc., issued to GEM Yield Bahamas Limited",
"Form of 2021 Warrants",
"Amended and Restated Registration Rights Agreement, by and among GEM Global Yield LLC SCS, GEM Yield Bahamas Limited and Cytocom Inc"
07/28/2021 8-K Appointed a new director
Docs: "Certificate of Amendment of Restated Certificate of Incorporation of Cleveland BioLabs, Inc",
"Executive Employment Agreement, as amended, by and among Cytocom Inc. and Michael K. Handley",
"Amendment No. 1 to Executive Employment Agreement, by and among Cytocom Inc. and Michael K. Handley",
"Amendment No. 2 to Executive Employment Agreement, by and among Cytocom Inc. and Michael K. Handley",
"Executive Employment Agreement, as amended, by and among Cytocom Inc. and Taunia Markvicka",
"Amendment No. 1 to Executive Employment Agreement, by and among Cytocom Inc. and Taunia Markvicka",
"Executive Employment Agreement, as amended, by and among Cytocom Inc. and Peter Aronstam",
"Amendment No. 1 to Executive Employment Agreement, by and among Cytocom Inc. and Peter Aronstam",
"Amendment No. 2 to Executive Employment Agreement, by and among Cytocom Inc. and Peter Aronstam",
"Cytocom Inc. Announces Completed Merger with Cleveland BioLabs"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy